Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by linpawson Jun 04, 2020 8:54am

126 Views

Post# 31110492

RE:RE:RE:RE:RE:Phase 2b Review - Medical Only

What is the fascination with WOMAC scores? If you think that release of WOMAC scores is going to change your mind on this company, then you shouldn't be invested in them in the first place. WOMAC is being compared between 346 and placebo!

So tired of hearing about WOMAC scores and explaining it to people who don't understand the study design and the outcomes.

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal